Statins and cognition: A systematic review and meta-analysis of short- and long-term cognitive effects

Mayo Clinic Proceedings

Volumn 88, Issue 11, 2013, Pages 1213-1221

  Swiger, Kristopher J ^a   Manalac, Raoul J ^a   Blumenthal, Roger S ^a   Blaha, Michael J ^a   Martin, Seth S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; ROSUVASTATIN;

ADULT; ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; DEMENTIA; DIGIT SYMBOL SUBSTITUTION TEST; DISEASE ASSOCIATION; DRUG EFFECT; DRUG USE; FOLLOW UP; HUMAN; INCIDENCE; META ANALYSIS; PROSPECTIVE STUDY; PSYCHOLOGIC TEST; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; VALIDATION STUDY;

EID: 84888861145     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.07.013     Document Type: Article

References (59)

1. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs. US FDA website. http://www.fda.gov/Drugs/ DrugSafety/ucm293101.htm. Accessed August 15, 2013.
2. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiology. 2004;23(1-2): 94-98.
3. Zandi PP, Sparks DL, Khachaturian AS, et al. Do statins reduce risk of incident dementia and Alzheimer disease? Arch Gen Psychiatry. 2005;62:217-224.
4. Bettermann K, Arnold AM, Williamson J, et al. Statins, risk of dementia, and cognitive function: secondary analysis of the Ginkgo Evaluation of Memory study. J Stroke Cerebrovasc Dis. 2012; 21(6):436-444.
5. Beydoun M, Beason-Held LL, Kitner-Triolo MH, et al. Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. J Epidemiol Community Health. 2011;65(11):949-957.
6. Evans M, Golomb B. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009;29(7): 800-811.
7. Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy. 2001;21(6):767-769.
8. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23(7): 871-880.
9. Parker BA, Polk DM, Rabdiya V, et al. Changes in memory function and neuronal activation associated with atorvastatin therapy. Pharmacotherapy. 2010;30(6):236e-240e.
10. Benito-León J, Louis ED, Vega S, Bermejo-Pareja F. Statins and cognitive functioning in the elderly: a population-based study. J Alzheimers Dis. 2010;21(1):95-102.
11. Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med. 2000;108(7):538-546.
12. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med. 2004; 117(11):823-829.
13. Trompet S, Vliet P, Craen AJM, et al. Pravastatin and cognitive function in the elderly: results of the PROSPER study. J Neurol. 2010;257(1):85-90.
14. Jukema JW, Cannon CP, De Craen AJM, Westendorp RGJ, Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol. 2012;60(10):875-881.
15. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.
16. Redberg RF, Katz MH. Healthy men should not take statins. JAMA. 2012;307(14):1491-1492.
17. Rosenberg M. Do you really need that statin? this expert says no. Huffpost Healthy Living: The Blog. The Huffington Post. http://www. huffingtonpost.com/martha-rosenberg/statins-b-1818370.html. Accessed August 15, 2013.
18. Parker-Pope T. A heart helper may come at a price for the brain. The Well Column. The New York Times. http://well.blogs.nytimes.com/2012/03/05/help-for- the-heart-comes-witha-price-for-the-brain/?-r=0. Accessed August 15, 2013.
19. Jick H, Zornberg G, Jick S. Statins and the risk of dementia. Lancet. 2000;356(9242):1627-1631.
20. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57(10):1439-1443.
21. Rea TD, Breitner JC, Psaty BM, et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol. 2005;62(7):1047-1051.
22. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
23. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-1630.
24. Rodriguez EG, Dodge HH, Birzescu MA, Stoehr GP, Ganguli M. Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study. J Am Geriatr Soc. 2002;50(11):1852-1856.
25. Zhou B, Teramukai S, Fukushima M. Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis. Dement Geriatr Cogn Disord. 2007;23(3):194-201.
26. Wong WB, Lin VW, Boudreau D, Devine EB. Statins in the prevention of dementia and Alzheimer's disease: a meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiol Drug Saf. 2013;22(4):345-358.
27. Song Y, Nie H, Xu Y, Zhang L, Wu Y. Association of statin use with risk of dementia: a meta-analysis of prospective cohort studies [published online ahead of print March 6, 2013]. Geriatr Gerontol Int. doi:10.1111/ggi.12044.
28. Haynes RB, McKibbon KA, Wilczynski NL, Walter SD, Werre SR; Hedges Team. Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey. BMJ. 2005;330(7501):1179-1182.
29. Wechsler D. Wechsler Adult Intelligence Scale. 3rd ed. San Antonio, TX: Psychological Corp; 1997.
30. Higgins J. Chapter 8: assessing risk of bias in included studies: Table 8.5 a. In: Cochrane Handbook for Systematic Reviews of Interventions. http://handbook.cochrane.org/. Accessed August 6, 2012.
31. WellsGA, Shea B,O'Connell D, et al. TheNewcastle-OttawaScale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.htm. Accessed August 15, 2013.
32. Harrison RW, Ashton CH. Do cholesterol-lowering agents affect brain activity? a comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol. 1994; 37(3):231-236.
33. Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clini Pharmacol. 1994;34(10): 989-996.
34. Cutler N, Sramek J, Veroff A, Block G, Stauffer L, Lines C. Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia. Br J Clin Pharmacol. 1995;39(3):333-336.
35. Gengo F, Cwudzinski D, Kinkel P, Block G, Stauffer L, Lines C. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin Cardiol. 1995;18(4): 209-214.
36. Parale GP, Baheti NN, Kulkarni PM, Panchal NV. Effects of atorvastatin on higher functions. Eur J Clin Pharmacol. 2006;62(4): 259-265.
37. Summers MJ, Oliver KR, Coombes JS, Fassett RG. Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial. Pharmacotherapy. 2007;27(2):183-190.
38. Berk-Planken I, de Konig I, Stolk R, Jansen H, Hoogerbrugge N. Atovastatin, diabetic dyslipidemia, and cognitive functioning. Diabetes Care. 2002;25(7):1250-1251.
39. Gibellato MG, Moore JL, Selby K, Bower EA. Effects of lovastatin and pravastatin on cognitive function in military aircrew. Aviat Space Environ Med. 2001;72(9):805-812.
40. Santanello NC, Barber BL, Applegate WB, et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J Am Geriatr Soc. 1997;45(1):8-14.
41. Glasser SP, Wadley V, Judd S, et al. The association of statin use and statin type and cognitive performance: analysis of the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study. Clin Cardiol. 2010;33(5):280-288.
42. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol. 2009;67(1):99-109.
43. Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci. 2002;57(7):414-418.
44. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol. 2002;59(3):378-384.
45. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in communitydwelling elderly people. Arch Neurol. 2002;59(2):223-227.
46. Dufouil C, Richard F, Fiévet N, et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three- City Study. Neurology. 2005;64(9):1531-1538.
47. Solomon A, Kåreholt I, Ngandu T, et al. Serum total cholesterol, statins and cognition in non-demented elderly. Neurobiol Aging. 2009;30(6):1006-1009.
48. Bernick C, Katz R, Smith NL, et al. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology. 2005;65(9):1388-1394.
49. Sparks DL, Kryscio RJ, Connor DJ, et al. Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort. Neurodegener Dis. 2010;7(1-3): 183-186.
50. Li G, Higdon R, Kukull WA, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology. 2004;63(9):1624-1628.
51. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007;5:20.
52. Li G, Shofer JB, Rhew IC, et al. Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc. 2010;58(7):1311-1317.
53. Arvanitakis Z, Schneider JA, Wilson RS, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology. 2008;70(19, pt 2):1795-1802.
54. CramerC,HaanMN,Galea S, Langa KM, Kalbfleisch JD.Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology. 2008;71(5):344-350.
55. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity: the Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009;80(1):13-17.
56. Szwast SJ, Hendrie HC, Lane KA, et al. Association of statin use with cognitive decline in elderly African Americans. Neurology. 2007;69(19):1873- 1880.
57. Sparks DL, Kryscio RJ, Sabbagh MN, Connor DJ, Sparks LM, Liebsack C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res. 2008;5(4):416-421.
58. Ancelin M, Carriere I, Barberger-Gateau P, et al. Lipid lowering agents, cognitive decline, and dementia: the Three-City Study. J Alzheimers Dis. 2012;30(3):629-637.
59. Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin: the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol. 2011;57(16):1666-1675.